Nanion TWIns With Stem Cells as New facilities Are Opened in Japan and USA

Tokyo, Japan and Livingston, NJ, USA, January 22, 2015; Nanion is expanding on two continents as new state-of-the-art research and demonstration facilities are opened in Tokyo, Japan and Livingston, NJ, USA. The new facilities provide the opportunity for customers to see Nanion's entire product portfolio in action, from the Port-a-Patch to the SyncroPatch 384/768PE.

Nanion Technologies, an innovative German-based company providing high quality devices for ion channel research and drug discovery, recently expanded into new premises in both Japan and USA.

Nanion Technologies Inc. opened in 2008 and due to expansion of personnel and devices it has now moved to larger premises in Livingston, NJ, with fully equipped laboratory facilities for validation experiments and demonstrations of the entire Nanion product range.

Rodolfo Haedo, VP of Nanion Technologies Inc. says about the move:

"We are very excited to move to these new, larger and more modern premises. We have had huge interest in the SyncroPatch 384/768PE high throughput screening tool since its launch in 2013 and have an ever-increasing installed base of the instruments in the US. The SyncroPatch 384PE has been so well received by customers so far and we see a bright future for sales this year, as well as for our other Nanion instrumentation in the US. These new premises will give us the opportunity to exhibit our complete product range to its full potential".

In Tokyo, Japan, Nanion has opened a new research laboratory within the Tokyo Women's Medical University - Waseda University Joint Institution for Advanced Biomedical Sciences (TWIns) . TWIns is a leading facility for induced pluripotent stem (iPS) cell research where Nanion has established a close collaboration with the Tokyo Women's Medical University (TWMU) to combine the use of iPS cells on Nanion's devices. Customers will be able to visit the facility to see the Nanion platforms in action with cells and receive high-quality support including iPS cardiomyocytes and neurons. Nanion Japan's expert electrophysiologist and general manager, Atsushi Ohtsuki, says about the new premises:

"TWIns is a recognized institute for stem cell research with an excellent reputation. Our collaboration with TWMU will enable optimal performance of iPS cells on Nanion's platform. We will have the full range of Nanion's products available for scientific support or demonstrations in this new state-of-the-art *facility in the heart of Tokyo, and look forward to welcoming both potential and existing customers to visit us here."*

About Nanion Technologies

Nanion Technologies was founded in 2002 as a spin-off from the University of Munich, Center for Nanoscience (CeNS). Over the last 13 years it has grown to a strong company with over 80 employees worldwide. Nanion has its headquarters in Munich, Germany, and has daughter companies in the USA and China, with distribution partners in 7 other countries, including Japan. Nanion has been recognized for its quality and innovation by being twice nominated for the Federal President's Award for Technology and Innovation (Deutscher Zukunftspreis) in 2007 and 2014. The company has become known for its high quality instruments for ion channel research (Port-a-Patch, Patchliner and SyncroPatch product families) and has over the years expanded its product range to include cardiotoxicity

screening (CardioExcyte 96), parallel bilayer recordings (Orbit 16), and parallel membrane transporter protein recordings (SURFE2R). Since 2014, Nanion carries Axion's multi-electrode array (MEA) systems in Europe and China.

Contact Information:
Rodolfo Haedo, VP Nanion Technologies Inc., email: info@naniontech.com, tel: +1 888-9-NANION
Atsushi Ohtsuki, General Manager Japan, Nanion Technologies, email: ohtsuki@nanion.jp,
tel: +81 3 6457 8773

Press Contacts:
Cecilia Farre, Marketing Director, email: cecilia.farre@nanion.de, tel: +49 89 218997973, www.nanion.de